{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:11:42Z","timestamp":1793398302006,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fogarty International Centre of the National Institutes of Health, US","award":["D43 TW010055"],"award-info":[{"award-number":["D43 TW010055"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-14061-4","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:09:29Z","timestamp":1784567369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exposure to the four first-line anti-tuberculosis drugs and treatment outcomes: a target trial emulation study in Ghana"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1671-1320","authenticated-orcid":false,"given":"Michael","family":"Opoku-Mireku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awewura","family":"Kwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret Y. M.","family":"Lartey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divine Aseye Yao","family":"Amenuke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwasi Adjepong","family":"Twum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla A.","family":"Nortey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Ansah","family":"Manu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwadwo Ansah","family":"Koram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"14061_CR1","unstructured":"WHO. Global Tuberculosis Report 2024 [Internet]. 2024 [cited 2025 Jan 23]. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024."},{"key":"14061_CR2","unstructured":"World Bank Group. World Bank Open Data [Internet]. Washington (DC): World Bank Group; 2025 [cited 2025 Mar 10]. Available from: https:\/\/data.worldbank.org."},{"issue":"6","key":"14061_CR3","doi-asserted-by":"publisher","first-page":"e0252819","DOI":"10.1371\/journal.pone.0252819","volume":"16","author":"AA Sylverken","year":"2021","unstructured":"Sylverken AA, Kwarteng A, Twumasi-Ankrah S, Owusu M, Arthur RA, Dumevi RM, et al. The burden of drug resistance tuberculosis in Ghana; results of the First National Survey. PLoS ONE. 2021;16(6):e0252819. https:\/\/doi.org\/10.1371\/journal.pone.0252819 . PubMed PMID: 34111159; PubMed Central PMCID: PMC8191906.","journal-title":"PLoS ONE"},{"issue":"2","key":"14061_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/cis353","volume":"55","author":"JG Pasipanodya","year":"2012","unstructured":"Pasipanodya JG, Srivastava S, Gumbo T. Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy. Clin Infect Dis. 2012;55(2):169\u201377. https:\/\/doi.org\/10.1093\/cid\/cis353.\u00a0","journal-title":"Clin Infect Dis"},{"issue":"12","key":"14061_CR5","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/infdis\/jir658","volume":"204","author":"S Srivastava","year":"2011","unstructured":"Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability. J Infect Dis. 2011;204(12):1951\u20139. https:\/\/doi.org\/10.1093\/infdis\/jir658.","journal-title":"J Infect Dis"},{"issue":"6","key":"14061_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.5588\/ijtld.15.0803","volume":"20","author":"L Mota","year":"2016","unstructured":"Mota L, Al-Efraij K, Campbell JR, Cook VJ, Marra F, Johnston J. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(6):819\u201326. https:\/\/doi.org\/10.5588\/ijtld.15.0803.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"14061_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5588\/ijtld.19.0025","volume":"24","author":"R Perumal","year":"2020","unstructured":"Perumal R, Naidoo K, Naidoo A, Ramachandran G, Requena-Mendez A, Sekaggya-Wiltshire C, et al. A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes. Int J Tuberc Lung Dis. 2020;24(1):48\u201364.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"14061_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.7196\/SAMJ.2023.v113i3.16761","volume":"113","author":"R Perumal","year":"2023","unstructured":"Perumal R, Naidoo K, Naidoo A, Padayatchi N. Clinical impact of plasma concentrations of first-line antituberculosis drugs. S Afr Med J. 2023;113(3):148\u201353. https:\/\/doi.org\/10.7196\/SAMJ.2023.v113i3.16761.","journal-title":"S Afr Med J"},{"key":"14061_CR9","doi-asserted-by":"publisher","unstructured":"Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D, et al. Pharmacokinetics of the first-line antituberculosis drugs in Ghanaian children with tuberculosis with or without HIV coinfection. Antimicrob Agents Chemother. 2017;61(2):e01701-16. https:\/\/doi.org\/10.1128\/AAC.01701-16.","DOI":"10.1128\/AAC.01701-16"},{"issue":"4","key":"14061_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jpids\/piv035","volume":"5","author":"A Kwara","year":"2016","unstructured":"Kwara A, Enimil A, Gillani FS, Yang H, Sarfo AM, Dompreh A, et al. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection. J Pediatr Infect Dis Soc. 2016;5(4):356\u201365. https:\/\/doi.org\/10.1093\/jpids\/piv035.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"2","key":"14061_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jac\/dkr445","volume":"67","author":"N Saleri","year":"2012","unstructured":"Saleri N, Demb\u00e9l\u00e9 SM, Villani P, Carvalho ACC, Cusato M, Bonkoungou V, et al. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. J Antimicrob Chemother. 2012;67(2):469\u201372. https:\/\/doi.org\/10.1093\/jac\/dkr445 . PubMed PMID: 22028201.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"14061_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.5588\/ijtld.15","volume":"20","author":"MJ Maze","year":"2016","unstructured":"Maze MJ, Paynter J, Chiu W, Hu R, Nisbet M, Lewis C. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2016;20(7):955\u201360. https:\/\/doi.org\/10.5588\/ijtld.15. .0792 PubMed PMID: 27287650.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"issue":"5152","key":"14061_CR13","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.4414\/smw.2015.14223","volume":"145","author":"M Meloni","year":"2015","unstructured":"Meloni M, Corti N, M\u00fcller D, Henning L, Gutteck U, von Braun A, et al. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges. Swiss Med Wkly. 2015;145(5152):5152. https:\/\/doi.org\/10.4414\/smw.2015.14223.","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"14061_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/AAC.00693-15","volume":"60","author":"JS Park","year":"2015","unstructured":"Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, et al. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. Antimicrob Agents Chemother. 2015;60(1):92\u20138. https:\/\/doi.org\/10.1128\/AAC.00693-15 . PubMed PMID: 26459901; PubMed Central PMCID: PMC4704228.","journal-title":"Antimicrob Agents Chemother"},{"key":"14061_CR15","doi-asserted-by":"publisher","unstructured":"Egelund EF, Alsultan A, Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharmacol Ther. 2015;9(4). https:\/\/doi.org\/10.1002\/cpt.180.","DOI":"10.1002\/cpt.180"},{"issue":"1","key":"14061_CR16","doi-asserted-by":"publisher","first-page":"e1002202","DOI":"10.1371\/journal.pmed.1002202","volume":"14","author":"EA Kendall","year":"2017","unstructured":"Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, et al. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLOS Med. 2017;14(1):e1002202. https:\/\/doi.org\/10.1371\/journal.pmed.1002202.","journal-title":"PLOS Med"},{"issue":"8","key":"14061_CR17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","volume":"34","author":"EL Fu","year":"2023","unstructured":"Fu EL. Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How? J Am Soc Nephrol JASN. 2023;34(8):1305\u201314. PubMed PMID: 37131279; PubMed Central PMCID: PMC10400102.","journal-title":"J Am Soc Nephrol JASN"},{"issue":"15","key":"14061_CR18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","volume":"62","author":"CA Peloquin","year":"2002","unstructured":"Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs. 2002;62(15):2169\u201383. https:\/\/doi.org\/10.2165\/00003495-200262150-00001.","journal-title":"Drugs"},{"issue":"12","key":"14061_CR19","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1086\/599040","volume":"48","author":"S Chideya","year":"2009","unstructured":"Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana. Clin Infect Dis. 2009;48(12):1685\u201394. https:\/\/doi.org\/10.1086\/599040.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"14061_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1086\/431984","volume":"41","author":"JW Tappero","year":"2005","unstructured":"Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum Concentrations of Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in Botswana. Clin Infect Dis. 2005;41(4):461\u20139. https:\/\/doi.org\/10.1086\/431984.","journal-title":"Clin Infect Dis"},{"key":"14061_CR21","unstructured":"WHO. Definitions and reporting framework for tuberculosis \u2013 2013 revision (updated December 2014 and January 2020). 2013."},{"issue":"9","key":"14061_CR22","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","volume":"208","author":"JG Pasipanodya","year":"2013","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464\u201373. https:\/\/doi.org\/10.1093\/infdis\/jit352 . PubMed PMID: 23901086; PubMed Central PMCID: PMC3789573.","journal-title":"J Infect Dis"},{"key":"14061_CR23","first-page":"1","volume-title":"Community involvement in tuberculosis care and prevention: towards partnerships for health: guiding principles and recommendations based on a WHO review","author":"World Health Organization, editor","year":"2008","unstructured":"World Health Organization, editor. Community involvement in tuberculosis care and prevention: towards partnerships for health: guiding principles and recommendations based on a WHO review. Geneva, Switzerland: World Health Organization; 2008. p. 1."},{"key":"14061_CR24","unstructured":"Ministry of Health, Ghana National Drugs Programme. Standard treatment guidelines. 7th ed. Accra: Ministry of Health; 2017."},{"key":"14061_CR25","unstructured":"Lixoft SAS, a Simulations Plus company. Monolix (Version 2023R1) [computer software]. Antony (France): Lixoft SAS; 2023. Available from:"},{"issue":"1","key":"14061_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/17512433.2017.1246179","volume":"10","author":"B Devaleenal Daniel","year":"2017","unstructured":"Devaleenal Daniel B, Ramachandran G, Swaminathan S. The challenges of pharmacokinetic variability of first-line anti-TB drugs. Expert Rev Clin Pharmacol. 2017;10(1):47\u201358. https:\/\/doi.org\/10.1080\/17512433.2017.1246179 . PubMed PMID: 27724114.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"14061_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/23744235.2024.2309348","volume":"56","author":"T Sileshi","year":"2024","unstructured":"Sileshi T, Makonnen E, Telele NF, Barclay V, Zumla A, Aklillu E. Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis. Infect Dis Lond Engl. 2024;56(4):308\u201319. PubMed PMID: 38315168; PubMed Central PMCID: PMC11134291.","journal-title":"Infect Dis Lond Engl"},{"issue":"4","key":"14061_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268\u201374. https:\/\/doi.org\/10.7326\/M16-2607 . PubMed PMID: 28693043.","journal-title":"Ann Intern Med"},{"key":"14061_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00377.x","author":"H Bang","year":"2005","unstructured":"Bang H, Robins JM. Biometrics. 2005;61(4):962\u201373. https:\/\/doi.org\/10.1111\/j.1541-0420.2005.00377.x."},{"issue":"6","key":"14061_CR30","doi-asserted-by":"publisher","first-page":"ofad255","DOI":"10.1093\/ofid\/ofad255","volume":"10","author":"K Houck","year":"2023","unstructured":"Houck K, Chakhaia T, Gorvetzian S, Critchley JA, Schechter MC, Magee MJ. Diabetes Mellitus and Tuberculosis Treatment Outcomes: Interaction Assessment Between Hyperglycemia and Human Immunodeficiency Virus in the State of Georgia, 2015\u20132020. Open Forum Infect Dis. 2023;10(6):ofad255. https:\/\/doi.org\/10.1093\/ofid\/ofad255.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"14061_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.5588\/ijtld.18.0433","volume":"23","author":"P Huangfu","year":"2019","unstructured":"Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2019;23(7):783\u201396. https:\/\/doi.org\/10.5588\/ijtld.18.0433 . PubMed PMID: 31439109.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"issue":"7","key":"14061_CR32","doi-asserted-by":"publisher","first-page":"e087218","DOI":"10.1136\/bmjopen-2024-087218","volume":"14","author":"H Mekonen","year":"2024","unstructured":"Mekonen H, Negesse A, Dessie G, Desta M, Mihiret GT, Tarik YD, et al. Impact of HIV coinfection on tuberculosis treatment outcomes in Ethiopia: a systematic review and meta-analysis. BMJ Open. 2024;14(7):e087218. https:\/\/doi.org\/10.1136\/bmjopen-2024-087218 . PubMed PMID: 38969385; PubMed Central PMCID: PMC11228389.","journal-title":"BMJ Open"},{"issue":"1","key":"14061_CR33","doi-asserted-by":"publisher","first-page":"106175","DOI":"10.1016\/j.jinf.2024.106175","volume":"89","author":"F Wagnew","year":"2024","unstructured":"Wagnew F, Alene KA, Kelly M, Gray D. Undernutrition increases the risk of unsuccessful treatment outcomes of patients with tuberculosis in Ethiopia: A multicenter retrospective cohort study. J Infect. 2024;89(1):106175. https:\/\/doi.org\/10.1016\/j.jinf.2024.106175 . PubMed PMID: 38729526.","journal-title":"J Infect"},{"issue":"2","key":"14061_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/jac\/dkx380","volume":"73","author":"O Clewe","year":"2018","unstructured":"Clewe O, Wicha SG, De Vogel CP, De Steenwinkel JEM, Simonsson USH. A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations. J Antimicrob Chemother. 2018;73(2):437\u201347. https:\/\/doi.org\/10.1093\/jac\/dkx380.","journal-title":"J Antimicrob Chemother"},{"issue":"43","key":"14061_CR35","doi-asserted-by":"publisher","first-page":"16741","DOI":"10.1074\/jbc.RA118.002693","volume":"293","author":"C Zhu","year":"2018","unstructured":"Zhu C, Liu Y, Hu L, Yang M, He ZG. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis. J Biol Chem. 2018;293(43):16741\u201350. https:\/\/doi.org\/10.1074\/jbc.RA118.002693.","journal-title":"J Biol Chem"},{"issue":"5","key":"14061_CR36","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/cid\/ciy","volume":"67","author":"C Sekaggya-Wiltshire","year":"2018","unstructured":"Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, et al. Delayed Sputum Culture Conversion in Tuberculosis\u2013Human Immunodeficiency Virus\u2013Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(5):708\u201316. https:\/\/doi.org\/10.1093\/cid\/ciy. 179 PubMed PMID: 29514175; PubMed Central PMCID: PMC6094003.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"8","key":"14061_CR37","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3855\/jidc.4696","volume":"8","author":"TN Gengiah","year":"2014","unstructured":"Gengiah TN, Botha JH, Soowamber D, Naidoo K, Abdool Karim SS. Low rifampicin concentrations in tuberculosis patients with HIV infection. J Infect Dev Ctries. 2014;8(8):987\u201393. https:\/\/doi.org\/10.3855\/jidc.4696 . PubMed PMID: 25116663.","journal-title":"J Infect Dev Ctries"},{"issue":"12","key":"14061_CR38","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1128\/AAC.05561-11","volume":"55","author":"SK Heysell","year":"2011","unstructured":"Heysell SK, Mtabho C, Mpagama S, Mwaigwisya S, Pholwat S, Ndusilo N, et al. Plasma Drug Activity Assay for Treatment Optimization in Tuberculosis Patients \u25bf. Antimicrob Agents Chemother. 2011;55(12):5819\u201325. https:\/\/doi.org\/10.1128\/AAC.05561-11 . PubMed PMID: 21968363; PubMed Central PMCID: PMC3232779.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"14061_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5588\/ijtld.19","volume":"24","author":"R Perumal","year":"2020","unstructured":"Perumal R, Naidoo K, Naidoo A, Ramachandran G, Requena-Mendez A, Sekaggya-Wiltshire C, et al. A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2020;24(1):48\u201364. https:\/\/doi.org\/10.5588\/ijtld.19.\u00a0","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"issue":"8","key":"14061_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/dmd.121","volume":"49","author":"Z Hussain","year":"2021","unstructured":"Hussain Z, Zhu J, Ma X. Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. Drug Metab Dispos. 2021;49(8):679\u201382. https:\/\/doi.org\/10.1124\/dmd.121.\u00a0","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"14061_CR41","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/cpt.3557","volume":"117","author":"TVB Malinga","year":"2025","unstructured":"Malinga TVB, Othman H, Paximadis M, Tiemessen CT, Ramsay M, Hazelhurst S, et al. Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub-Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases. Clin Pharmacol Ther. 2025;117(5):1338\u201357. https:\/\/doi.org\/10.1002\/cpt.3557 . PubMed PMID: 39829327; PubMed Central PMCID: PMC11993289.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"14061_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41591-018-0224-2","volume":"24","author":"MZ Imperial","year":"2018","unstructured":"Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):11. https:\/\/doi.org\/10.1038\/s41591-018-0224-2.","journal-title":"Nat Med"},{"issue":"4","key":"14061_CR43","doi-asserted-by":"publisher","first-page":"e1002773","DOI":"10.1371\/journal.pmed.1002773","volume":"16","author":"N Strydom","year":"2019","unstructured":"Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, et al. Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization. PLOS Med. 2019;16(4):e1002773. https:\/\/doi.org\/10.1371\/journal.pmed.1002773.","journal-title":"PLOS Med"},{"key":"14061_CR44","doi-asserted-by":"publisher","unstructured":"Paal M, Habler K, Northoff B, Vogeser M. Comparative routine therapeutic drug monitoring of mycophenolic acid in human plasma with HPLC-UV and isotope dilution LC-MS\/MS. Clin Lab. 2020;66(4):639-648. https:\/\/doi.org\/10.7754\/Clin.\u00a0","DOI":"10.7754\/Clin"},{"issue":"2","key":"14061_CR45","doi-asserted-by":"publisher","first-page":"e9425","DOI":"10.1002\/rcm.9425","volume":"37","author":"K Pr\u0161o","year":"2023","unstructured":"Pr\u0161o K, \u017didekov\u00e1 N, Porvazn\u00edk I, Solovi\u010d I, Mokr\u00fd J, Kertys M. A high-throughput LC\u2013MS\/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma. Rapid Commun Mass Spectrom. 2023;37(2):e9425. https:\/\/doi.org\/10.1002\/rcm.9425 . PubMed PMID: 36329637; PubMed Central PMCID: PMC9787364.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"4","key":"14061_CR46","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","volume":"41","author":"S Capiau","year":"2019","unstructured":"Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, et al. Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot\u2013Based Methods for Therapeutic Drug Monitoring. Ther Drug Monit. 2019;41(4):409. https:\/\/doi.org\/10.1097\/FTD.0000000000000643.","journal-title":"Ther Drug Monit"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14061-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:03:39Z","timestamp":1792076619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14061-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14061"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14061-4","relation":{"references":[{"id-type":"doi","id":"10.1111\/j.1541-0420.2005.00377.x","asserted-by":"subject"}],"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9255541\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Ethical clearance for the study was received from the Ghana Health Service Ethics Review Committee (GHS-ERC 002\/02\/21) and the KATH Ethics Committee (KATH IRB\/AP\/023\/21 and KATH IRB\/CR01\/023\/22). Written informed consent was obtained from all adult participants aged 18 years and above. For participants under the age of 18 (minors), written informed consent was obtained from their parents or legal guardians, and assent was also obtained from the minors themselves.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1811"}}